Assessing production variability in empty and filled adeno-associated viruses by single molecule mass analyses.

Molecular Therapy. Methods & Clinical Development Pub Date : 2022-11-15 eCollection Date: 2022-12-08 DOI:10.1016/j.omtm.2022.11.003
Eduard H T M Ebberink, Alisa Ruisinger, Markus Nuebel, Marco Thomann, Albert J R Heck
{"title":"Assessing production variability in empty and filled adeno-associated viruses by single molecule mass analyses.","authors":"Eduard H T M Ebberink,&nbsp;Alisa Ruisinger,&nbsp;Markus Nuebel,&nbsp;Marco Thomann,&nbsp;Albert J R Heck","doi":"10.1016/j.omtm.2022.11.003","DOIUrl":null,"url":null,"abstract":"<p><p>Adeno-associated viruses (AAVs) are useful vehicles for gene therapy because of their stability, low immunogenicity. and non-pathogenicity. However, disparity in AAV sample preparations (e.g., in capsid composition, DNA packaging, and impurities) gives rise to product heterogeneity, with possibly undesired effects on gene delivery. Ideally, AAV production should be with full control of AAV structure and genetic payload. Therefore, robust, efficient, and low material consuming methods are essential to characterize AAVs. Here, we use two emerging single-molecule techniques, mass photometry and Orbitrap-based charge-detection mass spectrometry, and show how they may efficiently and accurately characterize AAVs. We were able to resolve heterogeneous pools of particles, evaluating AAVs from two different serotypes (AAV8 and AAV2), produced by three independent production platforms, either lacking a genome or packed with a transgene. Together our data confirm that the different AAV production methods result in rather different and diverse AAV particle distributions. Especially for the packed AAVs, frequently additional subspecies were observed, next to the expected packed genome, mostly resulting from under- or overpackaging of genome material and/or residual empty particles. This work further establishes that both these single-particle techniques may become valuable tools in characterizing AAVs before they are used in gene therapy.</p>","PeriodicalId":517056,"journal":{"name":"Molecular Therapy. Methods & Clinical Development","volume":" ","pages":"491-501"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706604/pdf/","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Methods & Clinical Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtm.2022.11.003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/12/8 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Adeno-associated viruses (AAVs) are useful vehicles for gene therapy because of their stability, low immunogenicity. and non-pathogenicity. However, disparity in AAV sample preparations (e.g., in capsid composition, DNA packaging, and impurities) gives rise to product heterogeneity, with possibly undesired effects on gene delivery. Ideally, AAV production should be with full control of AAV structure and genetic payload. Therefore, robust, efficient, and low material consuming methods are essential to characterize AAVs. Here, we use two emerging single-molecule techniques, mass photometry and Orbitrap-based charge-detection mass spectrometry, and show how they may efficiently and accurately characterize AAVs. We were able to resolve heterogeneous pools of particles, evaluating AAVs from two different serotypes (AAV8 and AAV2), produced by three independent production platforms, either lacking a genome or packed with a transgene. Together our data confirm that the different AAV production methods result in rather different and diverse AAV particle distributions. Especially for the packed AAVs, frequently additional subspecies were observed, next to the expected packed genome, mostly resulting from under- or overpackaging of genome material and/or residual empty particles. This work further establishes that both these single-particle techniques may become valuable tools in characterizing AAVs before they are used in gene therapy.

通过单分子质量分析评估空和填充腺相关病毒的生产变异性。
腺相关病毒(aav)因其稳定性、低免疫原性而成为基因治疗的有效载体。和non-pathogenicity。然而,AAV样品制备的差异(如衣壳组成、DNA包装和杂质)导致产品异质性,可能对基因传递产生不良影响。理想情况下,AAV生产应该完全控制AAV结构和遗传载荷。因此,稳健、高效、低材料消耗的方法是表征aav的关键。在这里,我们使用了两种新兴的单分子技术,质谱法和基于轨道阱的电荷检测质谱法,并展示了它们如何有效和准确地表征aav。我们能够分析异质性颗粒池,评估来自两种不同血清型(AAV8和AAV2)的aav,这些aav由三个独立的生产平台生产,要么缺乏基因组,要么含有转基因。总之,我们的数据证实,不同的AAV生产方法导致相当不同和多样化的AAV颗粒分布。特别是对于包装的aav,在预期包装的基因组旁边,经常观察到额外的亚种,主要是由于基因组材料包装不足或过度包装和/或残留的空颗粒。这项工作进一步确立了这两种单颗粒技术在用于基因治疗之前可能成为表征aav的有价值的工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信